Osteonecrosis of the jaws produced by sunitinib : a systematic review
NAGIOS: RODERIC FUNCIONANDO

Osteonecrosis of the jaws produced by sunitinib : a systematic review

DSpace Repository

Osteonecrosis of the jaws produced by sunitinib : a systematic review

Show simple item record

dc.contributor.author Vallina, Carmen es
dc.contributor.author Ramírez Martínez Acitores, Lucía es
dc.contributor.author Torres García Denche, Jesús es
dc.contributor.author Casañas Gil, Elisabeth es
dc.contributor.author Hernández Vallejo, Gonzalo es
dc.contributor.author López-Pintor Muñoz, Rosa Mª es
dc.date.accessioned 2019-07-02T09:55:57Z
dc.date.available 2019-07-02T09:55:57Z
dc.date.issued 2019 es
dc.identifier.uri https://hdl.handle.net/10550/70666
dc.description.abstract Tyrosine kinase receptor family is involved in tumor growth, pathological angiogenesis and the progression (metastasis) of cancer. Sunitinib (Sutent®) inhibits members of the tyrosine kinase receptor family affecting the induction of angiogenesis and tumor progression. It is not clear if sunitinib increases the risk of osteonecrosis of the jaws (ONJ). The aim of this study was to carry out a systematic review about ONJ related to sunitinib, describing existing cases and possible associated risk factors. The PubMed/MEDLINE and Cochrane Library databases were searched without date restriction up to September 2018. We included prospective and retrospective observational studies, cross-sectional studies, clinical cases and series of cases, involving only human subjects. The methodological quality of the studies was assessed using The Joanna Briggs Institute (JBI) and Newcastle-Ottawa tools. A total of 13 studies fulfilled our inclusion criteria of which 7 were clinical cases, 5 case series and a retrospective study. All the articles were published between 2009 and 2018. Of the 102 patients treated with sunitinib analyzed in this study, 58 developed ONJ, being or having been treated with sunitinib and bisphosphonates or exclusively with sunitinib. In this systematic review, we found an increase of ONJ in patients who are medicated with other drugs different than bisphosphonates and denosumab. It is necessary that dentists, oral and maxillofacial surgeons as well as oncologists know the risk of ONJ that these antiresorptive drugs could have. There is a need to continue researching in this field with the aim of an increasing knowledge in this area and creating an adequate protocol of action for this population. es
dc.source Vallina, Carmen ; Ramírez Martínez Acitores, Lucía ; Torres García Denche, Jesús ; Casañas Gil, Elisabeth ; Hernández Vallejo, Gonzalo ; López-Pintor Muñoz, Rosa Mª. Osteonecrosis of the jaws produced by sunitinib : a systematic review. En: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, 24 3 2019: 2- es
dc.title Osteonecrosis of the jaws produced by sunitinib : a systematic review es
dc.type info:eu-repo/semantics/article en
dc.type info:eu-repo/semantics/publishedVersion en
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.identifier.doi 10.4317/medoral.22858 es

View       (1.413Mb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics